The phase III TH3RESA trial randomized ∼600 patients with advanced HER2-positive breast cancer, previously treated with at least two HER2-directed therapies (including trastuzumab and lapatinib) in a 2 : 1 ratio to T-DM1 or physician’s choice of treatment (HER2-targeted regimens for ...
The UK has conditionally approved Enhertu®(trastuzumab deruxtecan) as a monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer based on Phase II trial results. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional m...
Treatment of HER2 - positive metastatic breast cancer with lapatinib and capecit- abine in the lapatinib expanded access progra,nme, including efficacy in brain metastases - the UK experience[ J] . Br J Cancer, 2010, 102: 995- 1002.
近年来亦在多项科研计划中担任主持人或是共同主持人。 Quercetin inhibits truncated isoform of dopamine- and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer Han-Sheng Changa,1, Tzu-Chun Chengb,1, Shih-Hsin Tuc,d,1, Chih-Hsiung Wuc...
Piccart M J ,et al.Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer[J].European journal of cancer: official journal for European Organization for Research and Treatment of Ca...
HER2-positive Breast Cancer: Jocelyn’s Story : Episode 14 Video April 4, 2022 HER2-Positive Breast Cancer: Advice from Patients and CaregiversSophie Mueller provides advice for patients and caregivers with breast cancer who may be in similar situations. ...
CE: HER2-Positive Metastatic Breast Cancer and What Targeted Therapy Means for Managed Care Combining a Passion for Making a Difference With Entrepreneurship The Role of Telehealth in Oncology Pharmacy Is Increasingly Important CE: Innovations in Acute Graft-Versus-Host Disease: Pharm...
Virginia Kaklamani, MD, DSc, shares her excitement for an upcoming OncLive® "The TALK" program focusing on HER2-positive breast cancer updates from the SABCS 2021 Virtual Meeting. This is a modal window. The Playback API request failed for an unknown reason Error Code: ...
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were tr
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised, according to Dr. Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion of the presentation of upda